A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma-Reference-Cited by-同舟云学术

A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma

Published:2023-11-14 Issue:21 Volume:7 Page:6785-6789
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Strati Paolo¹,Jallouk Andrew¹^ORCID,Deng Qing¹,Li Xubin¹,Feng Lei²,Sun Ryan²^ORCID,Adkins Sherry¹,Johncy Swapna¹^ORCID,Cain Taylor¹,Steiner Raphael E.¹,Ahmed Sairah¹^ORCID,Chihara Dai¹^ORCID,Fayad Luis E.¹,Iyer Swaminathan P.¹^ORCID,Horowitz Sandra¹,Nastoupil Loretta J.¹^ORCID,Nair Ranjit¹,Hassan Ahmed³,Daoud Taher E.³,Hawkins Misha¹,Rodriguez Maria A.¹^ORCID,Shpall Elizabeth J.⁴,Ramdial Jeremy L.⁴,Kebriaei Partow⁴,Hong David S.⁵,Westin Jason R.¹^ORCID,Neelapu Sattva S.¹^ORCID,Green Michael R.¹

Affiliation:

1. 1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

2. 2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

3. 3Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX

4. 4Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX

5. 5Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/21/6785/2089219/blooda_adv-2023-010653-main.pdf

Reference17 articles.

1. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

2. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium;Nastoupil;J Clin Oncol,2020

3. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma;Strati;Blood,2021

4. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma;Topp;Br J Haematol,2021

5. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma;Oluwole;Br J Haematol,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy;Transplantation and Cellular Therapy;2024-01

2. Managing side effects: guidance for use of immunotherapies in multiple myeloma;Hematology;2023-12-08

3. ICANS prophylaxis: potentially transformative but elusive;Blood Advances;2023-11-14

4. A single-cell atlas of CD19 chimeric antigen receptor T cells;Cancer Cell;2023-11

5. Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies;Journal of Clinical Medicine;2023-09-22